The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.

Provided is a method of manufacturing a dental cord. The method including: producing a spinning solution by dissolving a fiber-moldable hydrophobic polymer material in a solvent; spinning the spinning solution to obtain a polymer nanofiber web composed of nanofibers and including three-dimensional micropores; laminating the polymer nanofiber web to obtain a polymer membrane; slitting the polymer membrane to obtain a nanofiber tape yarn; hydrophilic-treating the nanofiber tape yarn to obtain a hydrophilic-treated nanofiber tape yarn; plying and twisting the hydrophilic-treated nanofiber tape yarn with a covered yarn to obtain a nanofiber multiple yarn; and impregnating the nanofiber multiple yarn with a hemostatic agent.

A water-soluble sealant composition and a method for preparing the same which includes: adding soluble silver salt to a polyacrylic acid (PAA) solution; adjusting the pH of the PAA solution to 7-7.4; and heating the PAA solution to 90-125° C. The PAA has a molecular weight between 1000 to 8000. The composition includes a cross-linked poly(acrylic) silver matrix having affinity to proteins. The silver salt can be silver nitrate and/or silver acetate. The matrix may create hydrophilic zones which bind proteins. The composition when in contact with proteins may form hexagonal packing complexes of rod-like poly(acrylic) particles and proteins. It may form a clot made of multi-layered grid structure. In some cases, the complexes create loops that form cells comprising proteins e.g., albumin. The proteins may be of a body fluid such as blood, lymph and combinations thereof. The composition may be applied for a medical condition such as hemorrhage and lymphorrhea.

A medical dressing material having a chitosan fabric sponge structure according to the present disclosure has a structure in which chitosan fibers derived from a chitosan fabric are located on a porous structure formed using freeze-drying. Therefore, the medical dressing material has an excellent hemostatic effect and exudate-absorbing ability while exhibiting a strong tensile force, is convenient to use, and is capable of being molded into various forms so as to be widely used for wounds by an edged thing, scalds, pressure ulcers, diabetes-related foot disorders, or various surgical areas in various body tissue parts such as the spine, brain, eye, ear, nose, and cervix.

The present invention relates to a haemostatic material comprising a carrier layer and a material for wound contact comprising at least one haemostat in particulate, granular, powder, flake or short fibrous form. Such a haemostatic material is useful, for example, in reducing or stopping bleeding of a physiological target site in a person or animal, and can also be used to stem bleeding during medical procedures.

The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.

The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response. Advantageously, the tissue adhesives of the present invention are low cost and easy to produce, making them a promising substance to be used as a sealant for fluid leakages in soft tissue, as well as an easily tunable platform to further optimize the adhesive characteristics.

Disclosed is a fibrinogen composition. The fibrinogen composition comprises denatured fibrinogen hydrogel having a fibrinogen concentration ranging from 0.1 to 15 wt.-% and a fibrinogen hydrogel forming salt at a concentration less than a threshold concentration to form the fibrinogen hydrogel. In some examples, the fibrinogen composition is dehydrated denatured fibrinogen hydrogel, where the fibrinogen composition comprises salt at a concentration no greater than 20 wt.-%.

The present disclosure provides a foam nasal dressing for topically administering an active agent to a nasal cavity and for absorbing fluid discharge. The foam nasal dressing comprises a foamed core portion and a foamed shell portion arranged such that the foamed core portion is at least partially disposed within the foamed shell portion. The foamed shell portion has a porosity of greater than 80% and comprises a first phase-separated polymer and FIG. 1A an active agent. The foamed core portion comprises a second phase-separated polymer with the first and second phase-separated polymers being the same or different. The present disclosure also provides a method of forming the foam nasal dressing.

The present invention relates to improved hemostatic compositions comprising cellulose-based fibers supplemented with compounds, preparation and use thereof.